GlobeNewswire•January 15, 2019
The revolutionary drug delivery leader taps global finance strategist, William (Bill) Yuan, to head growing Board, which now includes prominent biotech investor, Dr. Gene Salkind
OXNARD, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors. These appointments will expand the size of the board to five with more members expected to be added in Q1.
Bill Yuan has served on CURE’s Board of Directors for 2 years and Dr. Gene Salkind has been an advisor and investor in CURE.
“Having previously worked with Bill to build and successfully exit two thriving companies, I can attest to his vast corporate governance experience and executive managerial prowess, and I am honored to gain Bill’s support as Chairman of CURE’s board of directors,” said Robert Davidson, CEO of CURE Pharmaceutical. “Bill’s qualifications, vision, outstanding skill set, and guidance will contribute to CURE’s profitability and create shareholder value. We are also thrilled that Dr. Salkind will now be contributing his vast clinical and life sciences knowledge into advancing CURE’s product pipeline as a board member.”
With more than 20 years of global finance experience, Bill Yuan has held positions with Wall Street’s tier one firms including Goldman Sachs (M&A), Morgan Stanley SB (Capital Markets), and Merrill Lynch (Corporate Institutional Asset Management). Bill has advised Fortune 100 companies across multiple continents, with a specialization in Asia, and China in particular. His leadership, track record and exclusive network of corporate and institutional clients and investors will contribute key building blocks for CURE to achieve the highest level of success.
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.
Forward Looking Statement
This press release contains forward-looking
statements that involve risks and uncertainties. There are important factors
that could cause actual results to differ materially from those in the
forward-looking statements. These factors include, without limitation, the
ability to successfully market our products, the difficulty in predicting the
timing or outcome of other product research and development efforts, potential
product characteristics and indications, marketing approvals and launches of
other products, the impact of pharmaceutical industry regulation, the impact of
competitive products and pricing, the acceptance and demand of new
pharmaceutical products, the impact of patents and other proprietary rights
held by competitors and other third parties and the ability to obtain financing
on favorable terms. The forward-looking statements in this press release
reflect the Company’s judgment as of the date of this press release. The
Company disclaims any intent or obligation to update these forward-looking
statements. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of our securities
in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction. On February
28, 2017, and ending on August 28, 2020, Liviakis Financial Communications,
Inc. (LFC) was retained by CURE Pharmaceutical Holding Corp. (CURR) in various
consulting capacities including strategic management planning, investor
relations and other business development responsibilities. LFC was
compensated 1,000,000 restricted common stock under rule 144. Officers
and employees of LFC will buy or sell shares in CURE Pharmaceutical Holding
Corp. prior, during or after this release. LFC advises CURE
Pharmaceutical Holding Corp. but does not provide investment advice. LFC
is not a registered investment advisor or broker-dealer. All material
provided regarding CURE Pharmaceuticals Holding Corp. including, but not
limited to its history, corporate status, and other developments was prepared
using information approved and signed off by CURE Pharmaceutical Holding Corp.
management as approved for public dissemination. Although the information
contained herein is believed to be reliable, LFC makes no warranties as to the
accuracy of the description of any of the content herein and accepts no
liability for how readers may choose to utilize it.